Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CLEC2D-TLR9 ISAC
- Development stage
- Preclinical
- Lead developer
- Immunitas Therapeutics
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Immunitas Therapeutics' CLEC2D-TLR9 ISAC is an investigational immune-stimulating antibody complex (ISAC) designed for cancer immunotherapy, particularly for tumors with low immunological activity or poor T-cell infiltration. The molecule consists of a fully human monoclonal antibody targeting CLEC2D (also known as LLT1) conjugated to a CpG oligonucleotide payload, which acts as a Toll-like receptor 9 (TLR9) agonist. By targeting CLEC2D, which is expressed on tumor cells and immunosuppressive myeloid cells, the complex delivers the TLR9 agonist specifically to the tumor microenvironment. This targeted delivery triggers the activation of myeloid cells, B cells, and plasmacytoid dendritic cells, promoting an inflammatory response that enhances the recruitment and function of T cells and NK cells, potentially turning "cold" tumors into immunologically "hot" ones.
- Other names
- anti-CLEC2D + TLR9anti-CLEC2D-TLR9 agonist immune stimulating antibody complexanti-CLEC-2D-TLR9 agonist immune stimulating antibody complexanti-CLEC 2D-TLR9 agonist immune stimulating antibody complexCLEC2D-TLR9-ISACCLEC-2D-TLR9-ISACCLEC 2D-TLR9-ISACLLT1-TLR9 ISACLLT-1-TLR9 ISACLLT 1-TLR9 ISAC
02
Targets
TLR9 (Toll-like receptor 9)CLEC2D (Lectin-like transcript 1)
Beyond the preview
Go deeper on CLEC2D-TLR9 ISAC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CLEC2D-TLR9 ISAC.